Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer

Oncotarget

Volumn 7, Issue 17, 2016, Pages 23251-23262

  Tan, Chye Ling ^a   Lim, Tse Hui ^a   Lim, Tony K H ^a   Tan, Daniel Shao Weng ^b   Chua, Yong Wei ^a   Ang, Mei Kim ^b   Pang, Brendan ^c   Lim, Chwee Teck ^d,e   Takano, Angela ^a   Lim, Alvin Soon Tiong ^a   Leong, Man Chun ^f   Lim, Wan Teck ^b,g  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f Clearbridge BioMedics Pte Ltd   (Singapore)

^g INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

ALK gene rearrangement; Circulating tumor cells; Fluorescent in situ hybridization; Lung cancer; Molecular diagnosis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ADULT; AGED; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; BLOOD SAMPLING; CELL COUNT; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FALSE POSITIVE RESULT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE REARRANGEMENT; GENE TARGETING; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NON SMALL CELL LUNG CANCER; TUMOR BIOPSY; ADENOCARCINOMA; BLOOD; FOLLOW UP; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR EMBOLISM;

ADENOCARCINOMA; ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84966680789     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8136     Document Type: Article

References (43)

1. American Cancer Society. Cancer Facts & Figures 2015. Atlanta: American Cancer Society; 2015. Accessed on 12 October 2015. Available from: http://www.cancer.org/ research/cancerfactsstatistics/cancerfactsfigures2015/index
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008; 83: 584-594.
3. Non-small cell lung cancer survival rate by stage. Am. Cancer Soc. Atlanta; 2015. Accessed on 14 March 2015. Available from: http://www.cancer.org/cancer/lungcancernon-smallcell/detailedguide/non-small-cell-lung-cancersurvival-rates
4. Lira ME, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EFPM, Choi Y La, Park K, et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn. 2013; 15: 51-61.
5. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-500.
6. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-566.
7. Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med. 2008; 59: 429-442.
8. Roskoski R Jr. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res. 2013; 68: 68-94.
9. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol. 2009; 4: 1450-1454.
10. Forde PM, Rudin CM. Crizotinib in the treatment of nonsmall-cell lung cancer. Expert Opin Pharmacother. 2012; 13: 1195-1201.
11. Shaw AT, Kim D-W, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, et al. Ceritinib in ALKrearranged non-small-cell lung cancer. N Engl J Med. 2014; 370: 1189-1197.
12. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013; 8: 823-859.
13. Reck M, Hermes A, Tan E-H, Felip E, Klughammer B, Baselga J. Tissue sampling in lung cancer: a review in light of the MERIT experience. Lung Cancer. 2011; 74: 1-6.
14. Chouaid C, Dujon C, Do P, Monnet I, Madroszyk A, Le Caer H, Auliac JB, Berard H, Thomas P, Lena H, Robinet G, Baize N, Bizieux-Thaminy A, et al. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer. 2014; 86: 170-173.
15. De Bruin E, McGranahan N, Yates L, Jamal-Hanjani M, Salm M, Mitter R, Shafi S, Murugaesu N, Rowan A, Gerlinger M, Wedge D, Horswell S, Varela I, et al. Intratumor heterogeneity in non-small cell lung cancer inferred by multi-region exome sequencing. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014; 74(19 Suppl): Abstract nr 983.
16. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer. 2003; 3: 453-458.
17. Mendoza M, Khanna C. Revisiting the seed and soil in cancer metastasis. Int J Biochem Cell Biol. 2009; 41: 1452-1462.
18. Alix-Panabierès C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013; 59: 110-118.
19. Khoo BL, Warkiani ME, Tan DSW, Bhagat AAS, Irwin D, Lau DP, Lim AST, Lim KH, Krisna SS, Lim WT, Yap YS, Lee SC, Soo RA, et al. Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. PLoS One. 2014; 9: e99409.
20. Bednarz-Knoll N, Alix-Panabières C, Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res. 2011; 13: 228.
21. Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T. Prognostic impact of circulating tumor cells assessed with the CellSearch SystemTM and AdnaTest BreastTM in metastatic breast cancer patients: the DETECT study. Breast Cancer Res. 2012; 14: R118.
22. Pailler E, Adam J, Barthélémy A, Oulhen M, Auger N, Valent A, Borget I, Planchard D, Taylor M, André F, Soria JC, Vielh P, Besse B, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALKpositive non-small-cell lung cancer. J Clin Oncol. 2013; 31: 2273-2281.
23. Ilie M, Long E, Butori C, Hofman V, Coelle C, Mauro V, Zahaf K, Marquette CH, Mouroux J, Paterlini-Bréchot P, Hofman P. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol. 2012; 23: 2907-2913.
24. Naoe M, Ogawa Y, Morita J, Omori K, Takeshita K, Shichijyo T, Okumura T, Igarashi A, Yanaihara A, Iwamoto S, Fukagai T, Miyazaki A, Yoshida H. Detection of circulating urothelial cancer cells in the blood using the CellSearch system. Cancer. 2007; 109: 1439-1445.
25. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schütze K, Capron F, Franco D, Pazzagli M, Vekemans M, Lacour B, Bréchot C, Paterlini-Bréchot P. Isolation by size of epithelial tumor cells. Am J Pathol. 2000; 156: 57-63.
26. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011; 192: 373-382.
27. Chinen LTD, de Carvalho FM, Rocha BMM, Aguiar CM, Abdallah EA, Campanha D, Mingues NB, de Oliveira TB, Maciel MS, Cervantes GM, Dettino ALA, Soares FA, Paterlini-Bréchot P, et al. Cytokeratin-based CTC counting unrelated to clinical follow up. J Thorac Dis. 2013; 5: 593-599.
28. Hofman V, Ilie MI, Long E, Selva E, Bonnetaud C, Molina T, Vénissac N, Mouroux J, Vielh P, Hofman P. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch AssayTM and the isolation by size of epithelial tumor cell method. Int J Cancer. 2011; 129: 1651-1660.
29. Yang P, Kulig K, Boland JM, Erickson-Johnson MR, Oliveira AM, Wampfler J, Jatoi A, Deschamps C, Marks R, Fortner C, Stoddard S, Nichols F, Molina J, et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol. 2012; 7: 90-97.
30. Srodon M, Westra WH. Immunohistochemical staining for thyroid transcription factor-1: a helpful aid in discerning primary site of tumor origin in patients with brain metastases. Hum Pathol. 2002; 33: 642-645.
31. Yoshida A, Tsuta K, Nitta H, Hatanaka Y, Asamura H, Sekine I, Grogan TM, Fukayama M, Shibata T, Furuta K, Kohno T, Tsuda H. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubuleassociated protein-like 4-anaplastic lymphoma kinasepositive lung adenocarcinomas. J Thorac Oncol. 2011; 6: 1677-1686.
32. Yoshida, A, Varella-Garcia M. Fluorescence in situ Hybridization (FISH). In: Tsao, Ming Sound, Hirsch, Fred R YY, editor. IASLC ATLAS ALK Test Lung Cancer. 10th ed. Internation Association for the study of Lung Cancer, Aurora,Co; 2013. page 23-4. Accessed on 12 October 2015. Available from: https://www.iaslc.org/publications/iaslcatlas-alk-testing-lung-cancer
33. Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, Crino L, Franklin WA, Varella-Garcia M. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010; 16: 5581-5590.
34. Klempner SJ, Cohen DW, Costa DB. ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. J Thorac Oncol. 2011; 6: 1439-1440.
35. Qu Y, Che N, Zhao D, Zhang C, Su D, Zhou L, Zhang L, Wang C, Zhang H, Wei L. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma. Tumour Biol. 2015; 36: 6417-6424.
36. Nishino M, Klepeis VE, Yeap BY, Bergethon K, Morales-Oyarvide V, Dias-Santagata D, Yagi Y, Mark EJ, Iafrate AJ, Mino-Kenudson M. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol. 2012; 25: 1462-1472.
37. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, et al. Clinical features and outcome of patients with non-smallcell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27: 4247-4253.
38. Faugeroux V, Pailler E, Auger N, Taylor M, Farace F. Clinical utility of circulating tumor cells in ALK-positive non-small-cell lung cancer. Front Oncol. 2014; 4: 281.
39. Kim H, Jang SJ, Chung DH, Yoo SB, Sun P, Jin Y, Nam KH, Paik JH, Chung JH. A comprehensive comparative analysis of the histomorphological features of ALKrearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype. PLoS One. 2013; 8: e76999.
40. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012; 18: 1472-1482.
41. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012; 4: 120ra17.
42. Travis WD, Brambilla E, Burke, AP, Marx A, Nicholson A. Lyon: IARC Press; 2015 World Health Organization Classification of Tumours of the Lung, Pleura, Thymus and Heart.
43. Hou HW, Warkiani ME, Khoo BL, Li ZR, Soo R a, Tan DS-W, Lim W-T, Han J, Bhagat AAS, Lim CT. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep. 2013; 3: 1259.